Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study

被引：0
|
作者：
Walter, Roland B. [1 ]
Medeiros, Bruno C. [2 ,3 ,4 ]
Gardner, Kelda M. [1 ]
Estey, Elihu H. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Stanford Univ, Div Hematol, Sch Med, Stanford, CA 94305 USA
[3] Stanford Univ, Div Oncol, Sch Med, Stanford, CA 94305 USA
[4] Stanford Univ, Stanford Canc Ctr, Stanford, CA 94305 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：670 / 670
页数：1
相关论文
共 50 条
  • [1] PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
    Walter, B.
    Medeiros, B.
    Nielsen-Stoeck, M.
    Harrington, E.
    Powell, B.
    Schiffer, C.
    Appelbaum, F.
    Estey, E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 29 - 30
  • [2] Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
    Walter, Roland B.
    Medeiros, Bruno C.
    Gardner, Kelda M.
    Orlowski, Kaysey F.
    Gallegos, Leonel
    Scott, Bart L.
    Hendrie, Paul C.
    Estey, Elihu H.
    [J]. HAEMATOLOGICA, 2014, 99 (01) : 54 - 59
  • [3] Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Walter, Roland B.
    Medeiros, Bruno C.
    Powell, Bayard L.
    Schiffer, Charles A.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 739 - 742
  • [4] Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia
    El Kinge, Abdul Rahman
    Hatourn, Hassan A.
    Mahfouz, Rami A.
    Otrock, Zaher K.
    Jabbour, Elias
    Kantarjian, Hagop
    Bazarbachi, Ali
    [J]. LEUKEMIA RESEARCH, 2009, 33 (04) : 565 - 566
  • [5] Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia
    Bayraktar, Ulas Darda
    Domingo, Gelenis Calzadilla
    Schmit, Jessica
    Pereira, Denise
    [J]. LEUKEMIA & LYMPHOMA, 2011, 52 (05) : 913 - 915
  • [6] Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Badar, Talha
    Murthy, Guru Subramanian Guru
    Runaas, Lyndsey
    Carlson, Karen-Sue B.
    Michaelis, Laura C.
    Harrington, Alexandra M.
    Atallah, Ehab L.
    Abedin, Sameem
    [J]. BLOOD, 2019, 134
  • [7] A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
    Nand, Sucha
    Othus, Megan
    Godwin, John E.
    Willman, Cheryl L.
    Norwood, Thomas H.
    Howard, Dianna S.
    Coutre, Steven E.
    Erba, Harry P.
    Appelbaum, Frederick R.
    [J]. BLOOD, 2013, 122 (20) : 3432 - 3439
  • [8] A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).
    Foster, Matthew C.
    Amin, Chirag
    Voorhees, Peter M.
    Van Deventer, Hendrik W.
    Richards, Kristy L.
    Ivanova, Anastasia
    Whitman, Jennifer
    Shea, Thomas C.
    [J]. BLOOD, 2009, 114 (22) : 808 - 809
  • [9] Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia
    Yamamoto, Ryusuke
    Yokoyama, Akihiro
    Yoneda, Mie
    Ohashi, Kota
    Hosoda, Toru
    Kagoo, Toshiya
    Boku, Saigen
    Ueno, Hironori
    Yano, Takahiro
    [J]. ANNALS OF HEMATOLOGY, 2014, 93 (12) : 2081 - 2082
  • [10] Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia
    Ryusuke Yamamoto
    Akihiro Yokoyama
    Mie Yoneda
    Kota Ohashi
    Toru Hosoda
    Toshiya Kagoo
    Saigen Boku
    Hironori Ueno
    Takahiro Yano
    [J]. Annals of Hematology, 2014, 93 : 2081 - 2082
12345